388 related articles for article (PubMed ID: 11869618)
1. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van der Heijden JF; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2002; (1):CD002001. PubMed ID: 11869618
[TBL] [Abstract][Full Text] [Related]
2. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
van Der Heijden JF ; Hutten BA; Büller HR; Prins MH
Cochrane Database Syst Rev; 2000; (4):CD002001. PubMed ID: 11034739
[TBL] [Abstract][Full Text] [Related]
3. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Crawford F
Cochrane Database Syst Rev; 2012 Oct; 10():CD002001. PubMed ID: 23076894
[TBL] [Abstract][Full Text] [Related]
4. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A; Sala Tenna A; Stewart M
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002001. PubMed ID: 28737834
[TBL] [Abstract][Full Text] [Related]
5. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.
Hutten BA; Prins MH
Cochrane Database Syst Rev; 2000; (3):CD001367. PubMed ID: 10908494
[TBL] [Abstract][Full Text] [Related]
6. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
van Den Belt AG; Prins MH; Lensing AW; Castro AA; Clark OA; Atallah AN; Burihan E
Cochrane Database Syst Rev; 2000; (2):CD001100. PubMed ID: 10796593
[TBL] [Abstract][Full Text] [Related]
7. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.
Hutten BA; Prins MH
Cochrane Database Syst Rev; 2006 Jan; (1):CD001367. PubMed ID: 16437432
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.
Quinlan DJ; McQuillan A; Eikelboom JW
Ann Intern Med; 2004 Feb; 140(3):175-83. PubMed ID: 14757615
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulation for people with cancer and central venous catheters.
Akl EA; Ramly EP; Kahale LA; Yosuico VE; Barba M; Sperati F; Cook D; Schünemann H
Cochrane Database Syst Rev; 2014 Oct; (10):CD006468. PubMed ID: 25318061
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.
Gould MK; Dembitzer AD; Doyle RL; Hastie TJ; Garber AM
Ann Intern Med; 1999 May; 130(10):800-9. PubMed ID: 10366369
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters.
Akl EA; Karmath G; Yosuico V; Kim SY; Barba M; Sperati F; Cook D; Schünemann HJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD006468. PubMed ID: 17636845
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.
Iorio A; Guercini F; Pini M
J Thromb Haemost; 2003 Sep; 1(9):1906-13. PubMed ID: 12941030
[TBL] [Abstract][Full Text] [Related]
13. Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.
Salazar CA; Malaga G; Malasquez G
Cochrane Database Syst Rev; 2010 Apr; 2010(4):CD005981. PubMed ID: 20393944
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
Louzada ML; Majeed H; Wells PS
Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
Cochrane Database Syst Rev; 2008 Apr; (2):CD006650. PubMed ID: 18425959
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation for patients with cancer and central venous catheters.
Akl EA; Vasireddi SR; Gunukula S; Yosuico VE; Barba M; Sperati F; Cook D; Schünemann H
Cochrane Database Syst Rev; 2011 Apr; (4):CD006468. PubMed ID: 21491394
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation for patients with cancer and central venous catheters.
Akl EA; Vasireddi SR; Gunukula S; Yosuico VE; Barba M; Sperati F; Cook D; Schünemann H
Cochrane Database Syst Rev; 2011 Feb; (2):CD006468. PubMed ID: 21328283
[TBL] [Abstract][Full Text] [Related]
18. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
van Dongen CJ; van den Belt AG; Prins MH; Lensing AW
Cochrane Database Syst Rev; 2004 Oct; (4):CD001100. PubMed ID: 15495007
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Vardi M; Zittan E; Bitterman H
Cochrane Database Syst Rev; 2009 Oct; (4):CD006771. PubMed ID: 19821386
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Akl EA; Labedi N; Barba M; Terrenato I; Sperati F; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Jun; (6):CD006650. PubMed ID: 21678361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
